The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

The proof is in the pudding: patient engagement in studying cannabidiol in mild cognitive impairment

Abstract Background Patient engagement (PE) in clinical trials has gained importance yet remains uncommon, particularly in patients with mild cognitive impairment (MCI), a critical precursor to Alzheimer’s disease (AD). Cannabidiol (CBD) shows potential in slowing MCI progression due to its neuropro...

Description complète

Détails bibliographiques
Auteurs principaux: Antonia Keck, Julia-Sophia Scheuermann, Petra Scheerbaum, Elmar Graessel, Kirsten R. Müller-Vahl
Format: Article
Langue:English
Publié: BMC 2025-01-01
Collection:BMC Complementary Medicine and Therapies
Sujets:
Mild cognitive impairment
Alzheimer’s disease
Cannabidiol
Cannabis-based medicine
Patient engagement
Patient and public involvement
Accès en ligne:https://doi.org/10.1186/s12906-025-04753-w

Internet

https://doi.org/10.1186/s12906-025-04753-w

Documents similaires